HMX Practice Pharmacology Quiz 2024.
Toxicity cause by binding of drug to its intended receptor in unintended tissue is an
example of ____ drug toxicity? ==on target
The classical small molecule drugs and the newer therapeutics, such as biologics, differ
in many ways. The defining difference between these drug modalities is their
==molecular weight
A monoclonal antibody is an example of a ==protein-based therapy
The ____________ index of a drug indicates the margin of safety of the drug.
==therapeutic
If the elimination rate of a drug does not increase when the concentration of the drug in
the plasma increases, this drug most likely follows ____________. ==zero-order
kinetics
Calculating the therapeutic dose of a drug involves a determination of the
____________ of the drug ==ED50
The goals of ____________ clinical trials are to determine the efficacy and tolerability of
an investigational drug, often in comparison to a standard of care medication for the
condition of interest. ==phase III
When determining the bioavailability of a drug administered by a given route, if a
____________ fraction of drug reaches the ____________, then the bioavailability,
expressed as a percentage, will be low.
small; systemic circulation
large; systemic circulation
small; portal circulation
large; portal circulation ==small; systemic circulation
Which of the following types of drugs will decrease the basal activity of a receptor?
==inverse agonist
A drug discovery approach that uses an endogenous ligand as the starting point for
development is considered to be ____________-centered drug discovery.
==compound
Which of the following is most likely the primary renal process by which a polar,
hydrophobic drug with a low affinity for plasma proteins moves from the plasma into the
urine? ==filtration
Toxicity cause by binding of drug to its intended receptor in unintended tissue is an
example of ____ drug toxicity? ==on target
The classical small molecule drugs and the newer therapeutics, such as biologics, differ
in many ways. The defining difference between these drug modalities is their
==molecular weight
A monoclonal antibody is an example of a ==protein-based therapy
The ____________ index of a drug indicates the margin of safety of the drug.
==therapeutic
If the elimination rate of a drug does not increase when the concentration of the drug in
the plasma increases, this drug most likely follows ____________. ==zero-order
kinetics
Calculating the therapeutic dose of a drug involves a determination of the
____________ of the drug ==ED50
The goals of ____________ clinical trials are to determine the efficacy and tolerability of
an investigational drug, often in comparison to a standard of care medication for the
condition of interest. ==phase III
When determining the bioavailability of a drug administered by a given route, if a
____________ fraction of drug reaches the ____________, then the bioavailability,
expressed as a percentage, will be low.
small; systemic circulation
large; systemic circulation
small; portal circulation
large; portal circulation ==small; systemic circulation
Which of the following types of drugs will decrease the basal activity of a receptor?
==inverse agonist
A drug discovery approach that uses an endogenous ligand as the starting point for
development is considered to be ____________-centered drug discovery.
==compound
Which of the following is most likely the primary renal process by which a polar,
hydrophobic drug with a low affinity for plasma proteins moves from the plasma into the
urine? ==filtration
